Publication date: May 15, 2019
This post was originally published on this site At the 2019 annual meeting of the American Academy of Neurology (AAN), Multiple Sclerosis News Today sat down with Bernd Kieseier, MD, global head of multiple sclerosis at Biogen, to discuss the company’s portfolio, latest data, and therapeutic development plans in the field of multiple sclerosis (MS). Kieseier said there is a need for a personalized approach to treat MS to find the exact therapy for each patient. -The highlight is clearly our commitment to identifying pathways toward a personalized medicine approach, optimizing the benefit-risk balance for our therapeutics, and taking the field forward by developing and offering new therapies,” Kieseier said. Neurofilament light as a disease biomarker This personalized medicine approach -has multiple flavors,” but Kieseier emphasized the possible use of a potential biomarker called neurofilament light chain (NfL), which is released from damaged neurons and, as such, can be a good marker of damage to the nervous system. -There’s good evidence that [NfL is] a marker you can use to dissect the trajectory of individual patients, like this is a patient that has a rather poor prognosis versus someone who is probably a little bit more stable,” Kieseier said, which might help in the process of decision-making in clinical practice, and allow clinicians to -say, ‘Well, this patient probably needs a different therapy. ‘ -The [anti-JCV antibody] index is a tool that defines the risk that you potentially might develop [PML],” Kieseier said, explaining that this can allow doctors and patients to accurately weigh the risks when considering what treatment is best. -I personally think that natalizumab (Tysabri) is one of the best therapies we have to offer to our patients, but the risk-benefit is a discussion the physician should have with the patient, and the antibody index is a tool to actually discuss the PML risk associated with natalizumab,” he said. Oral options: Tecfidera and Vumerity Kieseier also discussed data on two other Biogen MS therapies: Tecfidera (dimethyl fumarate) and Vumerity (diroximel fumarate; formerly BIIB098 or ALKS 8700). Kieseier said there is an -ongoing discussion” as further trials, such as a second Phase 2 trial of opicinumab and -other products that also address the component of repair,” are considered and planned for these and similar therapies, including BIIB061. Designing trials to truly assess repair is still -a work in progress,” Kieseier said, but added that he and colleagues are -super excited” at the prospect of MS therapies that would help the nervous system heal, not just prevent further damage. The post #AANAM – Biogen Offers Update on Development Plans for MS Therapies appeared first on Multiple Sclerosis News Today.
|disease||MESH||progressive multifocal leukoencephalopathy|
- Cancer Medication Shows Promise in Treating Dangerous Brain Infection PML, Small-scale Study Finds
- #AANAM – Research Suggests Extended Interval Dosing of Tysabri Can Decrease Risk of PML
- #AANAM – IV Therapy May Be More Effective Than Oral Treatment in Younger RRMS Patients, Research Suggests
- #AANAM – Tysabri Lowers Serum Neurofilament Light Levels in SPMS Patients, Phase 3 Trial Finds
- The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings.
- #AANAM – RRMS Patients Switching to Lemtrada Report Greater Satisfaction with Treatment and Improvements in Quality of Life